Acceptability and utilisation of patient‐initiated follow‐up for endometrial cancer amongst women from diverse ethnic and social backgrounds: A mixed methods study by Priyanga Kumarakulasingam (7239026) et al.
 1 
ACCEPTABILITY AND UTILISATION OF PATIENT-INITIATED FOLLOW-UP 1 
(PIFU) FOR ENDOMETRIAL CANCER AMONGST WOMEN FROM DIVERSE 2 
ETHNIC AND SOCIAL BACKGROUNDS: A MIXED METHODS STUDY 3 
 4 
1P Kumarakulasingam BSc (medical student), 2H McDermott PhD (lecturer in health 5 
psychology), 3N Patel (clinical nurse specialist), 3L Boutler (clinical nurse specialist), 6 
4DG Tincello MD (consultant gynaecologist), 3D Peel FRCR (consultant clinical 7 
oncologist), 1,3EL Moss PhD (consultant gynaecological oncologist) 8 
 9 
1Department of Cancer Studies, University of Leicester, Leicester,  10 
2School of Sport, Exercise and Health Sciences, Loughborough University,  11 
3Department of Gynaecological Oncology, University Hospitals of Leicester 12 
4Department of Health Sciences, University of Leicester, Leicester 13 
  14 
Address for correspondence:  15 
Dr Esther Moss PhD, ORCID 0000-0002-2650-0172, Department of Cancer Studies, 16 
University of Leicester, Leicester Royal Infirmary, Leicester, LE2 7LX.  Email: 17 
em321@le.ac.uk. Tel: 0044 2584861 18 
 19 
FUNDING 20 
This study was funded by the University of Leicester and the University Hospitals of Leicester 21 
Gynaecological Gynaecological Cancer Research fund. 22 
 23 
CONFLICT OF INTEREST STATEMENT 24 
 25 
None of the authors report conflict of interest. 26 
 27 
 2 
ABSTRACT 28 
Introduction 29 
A shift in focus towards risk stratification and survivorship in early stage endometrial cancer 30 
(EC) has led to the replacement of hospital follow-up (HFU) with patient-initiated follow-up 31 
(PIFU) schemes.  32 
Methods 33 
A mixed-methods study was undertaken prospectively to investigate utility and patient 34 
satisfaction with a newly introduced PIFU scheme.  35 
Results 36 
228 women were enrolled onto PIFU in the first 18 months, median age 65 years (range 42-90 37 
years). Twenty-four (10.5%) women were non British-White ethnicity. Forty-five women 38 
contacted the Clinical Nurse Specialist (CNS) at least once (19.7%), the primary reason being 39 
vaginal bleeding/discharge (42%). Contact was greater in first six months on the scheme 40 
compared to the second six months, and women who made contact were significantly younger 41 
than those who did not (57 years versus 65 years, p<0.001).  42 
Conclusions 43 
PIFU appears to be well received by the majority of women. Although many of the CNS 44 
contacts were due to physical symptoms, a number were for psychological support or 45 
reassurance. Younger women had greater CNS contact indicating that they may benefit from a 46 
greater level support. Patient feedback of the PIFU scheme was positive, with many women 47 
reporting that it enabled them to have more control over their own health.  48 
 49 
KEYWORDS: Endometrial cancer; follow up; patient-initiated; quality of life; patient 50 
satisfaction 51 
 52 
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INTRODUCTION 53 
The incidence of endometrial cancer (EC) in the UK has increased by 65% over the past 40 54 
years making it not only the most common gynaecological cancer but the fourth most common 55 
malignancy in women, accounting for 3% of all new cancer diagnoses (UK). The majority of 56 
cases are diagnosed with early stage disease, which carries a good long-term prognosis with 5-57 
year disease-specific survivals in excess of 95% (Amant et al., 2005; UK). It is a disease 58 
typically affecting older women with the majority being over the age of 70 years at diagnosis 59 
and having co-morbidities, in particular obesity, diabetes and cardio-vascular disease (Parkin, 60 
Boyd, & Walker, 2011). 61 
 62 
Women diagnosed with an endometrial cancer have been traditionally followed-up through 63 
regular hospital review by a specialist gynaecological oncologist after completing their 64 
treatment (Colombo et al., 2011). Hospital follow-up (HFU) typically involves women being 65 
reviewed routinely by doctors and/or nurses who conduct a physical examination. The rationale 66 
for attending HFU is surveillance for cancer recurrence thus enabling early detection, prompt 67 
management and as a result a better long-term prognosis. The period of review has historically 68 
been for a minimum of five years since the majority of cancer recurrences occur within three 69 
years post treatment (Colombo et al., 2011).  The role of routine follow-up in early stage, low-70 
risk endometrial cancer (EC) however has been questioned since it does not appear to have an 71 
impact of long-term survival (Gadducci, Cosio, Fanucchi, Cristofani, & Genazzani, 2000; 72 
Owen & Duncan, 1996; Yoshiba et al., 2016).  In light of the rising incidence, low recurrence 73 
rate, population demographics and the lack clear clinical benefit of hospital follow-up in such 74 
cases, alternative follow-up schedules (Salani et al., 2011) and models have been developed, 75 
for example telephone follow-up (TFU) (Beaver et al., 2016) and patient-initiated follow-up 76 
(PIFU).  77 
 4 
 78 
PIFU, as the name suggests, is where patients are not routinely seen in hospital but instead have 79 
open access to Clinical Nurse Specialists (CNS) whom they can contact should they have 80 
concerns or if/when symptoms arise. The first UK national survey on the follow-up of 81 
gynaecological cancer patients reported that out of all the available follow-up schemes, PIFU 82 
was used instead of or as an adjunct to existing follow up models by 32% of the centres that 83 
responded (Leeson, Stuart, Sylvestre, Hall, & Whitaker, 2013). Despite the wide spread use of 84 
PIFU there are very few reports in the literature examining patient views or satisfaction with 85 
such schemes.  86 
 87 
A PIFU scheme was introduced in September 2014 at University Hospitals of Leicester (UHL) 88 
for early stage EC. Women who had received a diagnosis of early stage EC in the previous 5 89 
years and were under HFU were offered transfer to the PIFU scheme. Women with a new 90 
diagnosis were started on PIFU immediately following completion of their treatment. PIFU 91 
was led by the CNSs who would have an end of treatment appointment with the patient where 92 
they would provide them with their contact details and written information on the 93 
signs/symptoms that should prompt a medical review. A telephone call by the CNS to the 94 
patient was scheduled for 6 and 12 months to ensure that the patient was still happy to continue 95 
on the PIFU scheme and had the contact details should symptoms arise. No other contact with 96 
the medical team was organised. 97 
 98 
In order to ensure patient satisfaction with the scheme a prospective study was conducted 99 
investigating patients’ utilisation, personal opinions and attitudes towards the PIFU scheme.  100 
 101 
 102 
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METHODS 103 
A mixed methods study was undertaken following guidelines for qualitative research in order 104 
to ensure reliability and validity (BMJ, 2016). Mixed methods studies are increasingly used 105 
within health research to increase our understanding of health problems (Plano Clark & 106 
Creswell, 2010). This study utilized a sequential explanatory approach (Terrell, 2012) whereby 107 
the results from the distributed questionnaires informed the development of the semi-structured 108 
interview schedule. In addition, qualitative data added depth and understanding to the 109 
questionnaire findings.  110 
 111 
The introduction of the PIFU scheme at UHL was supported by the East Midlands 112 
Gynaecological Oncology Clinical Advisory Group (ECAG) and the UHL Cancer Board. The 113 
prospective audit of patient utility and satisfaction of the scheme was approved by the 114 
University Hospitals of Leicester audit team. Ethical approval was granted for the patient 115 
interviews (15/WM/0239). Women with a diagnosis of early stage low-risk EC and early stage 116 
intermediate risk EC who had completed adjuvant treatment, were enrolled onto the PIFU 117 
scheme in its first 18 months (September 2014 to March 2016) and were included in the study.  118 
 119 
Scheme utilisation 120 
Information was collated on the demographics of the patients, including age at diagnosis and 121 
ethnicity. The contemporaneous call log and individual patient records kept by the CNSs were 122 
reviewed and classified by primary reported reason for telephone contact: physical; 123 
psychological; practical. The data were analysed using GraphPad Prism (GraphPad Software, 124 
Inc, La Jolla, USA).  125 
 126 
 127 
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Patient satisfaction 128 
Quality of Life (EORTC QLQ-C30) and patient satisfaction questionnaires (Appendix 1) were 129 
posted to the women on the scheme at 6 and 12 months following enrolment. The QLQ-C30 130 
results were analysed using the EORTC QLQ-C30 scoring manual (Fayers & Bjordal, 2001) 131 
in order to give a score for Functioning, Symptoms and Global Health Status and were 132 
compared against the references values (Scott & Aaronson, 2008).  133 
 134 
Semi-Structured interviews 135 
Women enrolled on the PIFU scheme were invited to attend a face-to-face semi-structured 136 
interview with two female members of the research team (PK and EM) to discuss their views 137 
and opinions on PIFU. Both PK and EM are trained in interview techniques.  One of the 138 
interviewers was a member of the clinical gynaecological oncology team at the University 139 
Hospitals of Leicester. In order to achieve a wide sampling frame women were grouped in to 140 
British White (BW) (Group a) and non British White (non BW) (Group b) and then subdivided 141 
into women who transferred onto the PIFU scheme from HFU (Group A) and those who were 142 
started directly onto the PIFU scheme following their diagnosis (Group B). Women were 143 
selected randomly from each of the four groups (Aa, Ab, Ba, Bb) by hospital unit number and 144 
a written invitation was posted to their home address.  Invitations were sent out and interviews 145 
were conducted in an outpatients clinic room, until data saturation was achieved. An interview 146 
guide was used asking questions on their treatment journey, experiences and views on different 147 
follow up schemes and views of the future. Interviews were recorded with the knowledge and 148 
consent of the participants and subsequently transcribed verbatim. Due to the interviews being 149 
fully transcribed, field notes were not undertaken by either interviewer.  150 
 151 
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The interview data were analysed using the six-stage process of Thematic Analysis described 152 
by Braun & Clarke (2006) and managed using Nvivo software. Initially, the analysis was 153 
deductive but as the analysis progressed it became more inductive as new themes were 154 
identified in the data. The data transcripts were read and re-read to facilitate familiarisation 155 
with the data, and then coded line-by-line by the researchers (PK and HM). Repeated reading 156 
of the data allowed codes to be developed, which were subsequently grouped into themes. As 157 
the analysis progressed key themes were selected and further sub-themes were subsequently 158 
developed. A thematic map incorporating the identified codes was created in order to identify 159 
trends and associations. To ensure the trustworthiness of the coding the two researchers (PK 160 
and HM) independently coded the data and during discussions similar codes and interpretations 161 
were found to have been applied to the cross checked sections of data.  All experiences reported 162 
by participants were included in the analysis and represented in the manuscript. Triangulation 163 
was used at the interpretation stage of the study in order to consider the findings from the 164 
quantitative and qualitative aspects and determine their agreement or dissonance (Erzberger & 165 
Prein, 1997). 166 
 167 
 168 
RESULTS 169 
Over the 18-month study period 228 women with a diagnosis of an early stage EC were 170 
enrolled onto the PIFU scheme. The median age was 65 (range 42 - 90 years). The majority of 171 
women, 204 (89.5%), were BW and 24 (10.5%) were non BW (22 British South Asian (BSA) 172 
and 2 African/AfroCaribbean (AA)). One hundred and three women were diagnosed pre-173 
September 2014 and were transferred from routine hospital follow-up (HFU) onto the PIFU 174 
scheme. There were 125 women diagnosed post-September 2014 that were directly transferred 175 
onto the PIFU scheme. The median time on the PIFU scheme was 14 months (95% CI 12.9-176 
 8 
14.3 months). The total number of women in follow-up prior to September 2014 or who had 177 
completed adjuvant therapy was not known and therefore it was not possible to calculate the 178 
proportion of patients who moved to PIFU. Women in these groups were given the choice of 179 
PIFU rather than HFU by their supervising clinicians. Of the women diagnosed post-September 180 
2014 with early stage low-risk EC less than 5% were deemed not suitable for recruitment to 181 
PIFU, primarily due to mental health issues.  182 
 183 
Patient-Initiated Contact  184 
Forty-five women (19.7%) contacted the Clinical Nurse Specialists (CNS) at least once. 185 
Significantly more contact was made in the first six months of being entered onto the scheme 186 
as compared to the second six months (37/45 versus 8/45, Chi squared p<0.001). Women who 187 
were transferred onto PIFU directly also were more likely to make contact compared to women 188 
who had been under routine HFU and then transferred (30/125 women versus 15/103 women, 189 
Chi square p=0.075) and were significantly younger than women who did not contact (median 190 
age 57 years compared to 65 years, Mann Whitney p<0.001). Although women of non BW 191 
ethnicity were more likely to contact (6/24, 33.3%) compared to BW women (39/204, 19.1%) 192 
the difference was not statistically significant. Four women were transferred from PIFU back 193 
to HFU due to patient anxiety and multiple symptomatology.  194 
 195 
The primary reason for contacting the CNS were mainly due to physical symptoms (62%), such 196 
as vaginal bleeding/discharge or abdominal pain, however, 20% of the calls were for 197 
psychological support or reassurance. Another 2 calls were for practical assistance, for example 198 
help claiming benefits.   199 
 200 
 201 
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Quality of Life 202 
In total, 153 6-month and 109 12-month Quality of Life (QLQ) and Patient Satisfaction (PSQ) 203 
questionnaires were returned. There was no significant difference in Functioning Scale Scores 204 
(FSS) between the six-month and 12-month QLQs (Figure 1). For all of the functioning 205 
subscales, the scores from both 6 and 12 months were higher than the references values, 206 
indicating that the women on the PIFU scheme had a higher level of functioning than the 207 
reference populations ‘all cancer patients: female’ and ‘all cancer patients: stage 1-II’. The 208 
scores were also lower than the reference values for the symptoms scale score (SSS) (Figure 209 
2) and for the global health status score (GHSS) (Figure 3). There was no difference in the 210 
GHSS score between the 6- and 12-month QLQs, Mann Whitney p=0.564. 211 
 212 
Patient Satisfaction  213 
Patient feedback regarding the PIFU scheme was positive, with 62% of women in the 6-month 214 
PSQ reported they found it useful (very much/quite a bit) and only one patient (0.6%) reporting 215 
that they did not find the scheme useful at all. Dissatisfaction increased slightly at the 12-month 216 
PSQ with 4 women (3.6%) giving the response ‘not at all’ to the question ‘Overall how 217 
reassured are you by PIFU?’ but this contrasted with 63% of women who responded very 218 
much/quite a bit. In the PSQs 25 women (six-month PSQ) and 12 women (12-month PSQ) 219 
reported contacting the CNS with the most common reason being that they were worried about 220 
a symptom they had developed. The next most commonly reported reason was that they wanted 221 
to speak about worries and feelings that they were having. 222 
 223 
Patient Attitudes 224 
Of the 51 women contacted, 21 women agreed to (13 BW and 8 non BW) participate in a semi-225 
structured interview. Non BW women were offered translators, which two accepted and two 226 
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women brought a family member with them to translate. Interview times ranged from 20 to 58 227 
minutes.  228 
 229 
PIFU was reported as being the preferred follow-up model by nine women. Four women 230 
preferred HFU and five suggested a combination of HFU initially following treatment with 231 
transfer to PIFU after a short period of time, for example 12 months, would be better. Women 232 
that preferred the PIFU scheme commented on the importance of being able to carry on with 233 
their lives and being able to have more control over their own health whilst having the 234 
reassurance of direct access to the CNS if needed. For example, one 53-year-old non BW 235 
female stated; “It stops me having to worry about ‘I’ve got an appointment here to come and 236 
see this person’. I’m looking out for my own symptoms and know that if I ring up the secretary 237 
or the clinic and say ‘I have this issue, can I come and see somebody?’ I can come in. I don’t 238 
have to go via the GP is what I’m saying.” The main reason given for preferring hospital 239 
follow-up (HFU) was the reassurance of seeing somebody face-to-face as it was thought to be 240 
more personal. A 51-year-old BW female said; “I think I would have preferred to come back 241 
and seen, physically seen someone… I think it’s more just reassurance to meet somebody face 242 
to face about it. It’s a bit more personal.” No participants reported that they would have 243 
preferred to be seen by their general practitioner (GP) for follow-up.  244 
 245 
The majority of women on the PIFU scheme understood how to use the scheme. The overall 246 
feeling reported by participants was that it was easier and quicker to contact the CNS and they 247 
reported that they had confidence that the CNS would instigate any necessary investigations or 248 
appointments, rather than being seen in primary care for symptoms. The majority of the non 249 
BW women interviewed were of BSA ethnicity and they felt particularly reassured that they 250 
could communicate with a Gujarati/Hindi speaking CNS. A 59-year old non BW female said; 251 
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‘Yes. It’s very helpful because it’s in our language, whatever the problem is I can communicate 252 
it very well and I’m happy”. 253 
 254 
The main reason participants reported for not utilising the scheme was the fear of wasting the 255 
CNS’ time. For example, a 63 year-old BW female stated; “It’s too easy to think ‘I won’t 256 
bother’ because it, I don’t know, you feel like you’re bothering somebody.” Other reported 257 
reasons included either worrying about or ignoring symptoms participants thought might have 258 
been related to their endometrial cancer diagnosis. For example, a 53-year old non BW female 259 
said; “The only barrier that I think would stop them ringing in is if they worried that it has 260 
come back. Because you’ve got to get your mind around that one first before you go and ring”.  261 
 262 
‘Wasting the doctor’s time’ and the ‘unnecessary journey’ to a HFU appointment if women 263 
were asymptomatic were commonly reported barriers to attending HFU. A 63 year-old BW 264 
female said; 'It becomes a bit of a pain coming in every 4 months, every 6 months, when actually 265 
there’s not anything wrong with you and it’s a waste of your time, bus money, petrol money, 266 
whatever the consultant’s time, when there’s actually nothing wrong with you.' 267 
 268 
DISCUSSION 269 
Risk stratification with regard to patient follow-up is not a new concept in oncology. PIFU 270 
schemes have been developed for low-risk disease for several reasons, both patient and 271 
economic, across a range of specialties and diseases (Taneja, Su'a, & Hill, 2014). However, 272 
ensuring patient safety and satisfaction has to be the central goal when evaluating such 273 
schemes. In this mixed methods study we have used both quantitative and qualitative methods 274 
to ensure women are utilising PIFU and are accessing the CNSs when needed. The results of 275 
the two investigative methods have given complimentary information, with the quantitative 276 
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aspect determining the frequency/indication for contact and the interviews exploring women’s 277 
rationale for their behavior. Leeson et al., (Leeson et al., 2013) identified that there are a wide 278 
range of follow-up models currently in use in the UK for women who have been diagnosed 279 
with a gynaecological malignancy. Many centres reported using telephone (25%) or patient-280 
initiated (32%) follow up schemes, in contrast to ESMO guidance (Colombo et al., 2011), 281 
which supports a policy of regular follow up for all patients for 5 years.  282 
 283 
We have demonstrated that early stage EC patients experience a good quality of life post 284 
treatment, noticeably higher than the reference populations ‘all cancer patients: female’ and 285 
‘all cancer patients: stage I-II’ used for the EORTC-QLQ30. A strong theme that emerged in 286 
the interviews was that women understood that their risk of recurrence was low and did not 287 
want to keep being reminded of their diagnosis by attending HFU.  This may be interpreted as 288 
a self-management coping mechanism whereby the participants tried to leave their cancer 289 
experiences behind them in an attempt to adopt some form of normality.  Indeed, reminders of 290 
cancer have been found to induce fear and increased insecurity of cancer recurrence in breast 291 
cancer survivors (Drageset, Lindstrom, & Underlid, 2016). 292 
 293 
The fear of cancer recurrence can lead to cancer survivors employing specific self-management 294 
strategies to forget their cancer diagnosis.  Howard et al., (Howard et al., 2016) identified that 295 
adult childhood cancer survivors’ employed strategies such as avoiding contact with medical 296 
personnel and not attending hospital/clinic appointments in an attempt to forget their previous 297 
diagnosis.  In a further study by Zelman et al., (Zelman et al., 2004) participants reported that 298 
being able to forget about their cancer diagnosis, even for a short while, was an important 299 
determinant of a ‘desirable day’.  Returning to normal life has been identified as a highly 300 
motivating factor for recovery (Howard et al., 2016) and an important factor in coping with a 301 
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cancer diagnosis (Drageset, Lindstrom, & Underlid, 2010).  PIFU removes the need for patients 302 
to attend hospital appointments and it may be argued that this can facilitate their ‘return to 303 
normal’.  The good long-term prognosis of early stage EC and PIFU can help to change 304 
people’s perception that cancer is not necessarily a fatal disease but that they can have a life 305 
beyond their diagnosis. The change in focus toward patient survivorship is increasingly 306 
necessary and the importance of developing supported self-management pathways, helping 307 
patients to manage their own health and wellbeing can not only address unmet needs but can 308 
reduce the demand on support services.  309 
 310 
We have shown that PIFU for early stage EC is well received by our population. A recent 311 
randomised trial evaluating the effectiveness of nurse-led telephone follow-up (NTFU), 312 
compared to HFU, also reported high levels of patient satisfaction, with no detrimental physical 313 
or psychological effects (Beaver et al., 2016). Our scheme was not classified as a NTFU since 314 
the 6-monthly calls were not structured and did not ask questions on symptoms or wellbeing, 315 
merely ensured that the patient understood the purpose of the PIFU scheme and was happy to 316 
remain on it. We did identify that younger women and women from a non BW ethnicity were 317 
more likely to initiate contact, suggesting that they were in greater need of support from the 318 
CNS. A reason for this finding could be that psychological unmet needs have been shown to 319 
be significantly associated with age at diagnosis (Boyes, Girgis, D'Este, & Zucca, 2012). BSA 320 
cancer patients are reported to have twice the rate of self-reported depressive symptoms and 321 
five times the incidence of severe depression as compared to BW cancer patients (Lord et al., 322 
2013). Lord et al., (Lord et al., 2013) also reported that BSA patients used more maladaptive 323 
coping strategies, such as helplessness/hopelessness and fatalism, and experienced a heavier 324 
physical symptom burden as compared to BW patients. In our study the BSA women reported 325 
that they were very supportive of PIFU preferring not to attend the hospital, since this was felt 326 
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to be a sign of ongoing active disease rather than surveillance for disease that had been treated. 327 
It is essential when designing a PIFU scheme to ensure that the women who are enrolled have 328 
the capacity and insight to contact the CNS should an issue arise. Women who are non-English 329 
speakers are at particular risk of being disenfranchised and education sessions with their 330 
family/carers and the availability of interpreting services can enable women to participate in 331 
PIFU. Knowledge of the local community and its demographics can be helpful in planning 332 
services, for example Leicester has a high BSA population who are predominantly Gujarati 333 
speaking. An advantage of the Leicester PIFU scheme therefore is that one of the CNSs is a 334 
fluent Gujarati/Hindi speaker thereby enabling non-English speakers to access the scheme, 335 
another positive factor reported by the non BW women who were interviewed.  336 
 337 
CONCLUSION 338 
PIFU for early stage EC appears to be well received by the majority of women. Although many 339 
of the CNS contacts were related to physical symptoms, many were for psychological support 340 
or reassurance. Younger women had greater CNS contact indicating that they may benefit from 341 
a greater level of CNS support. Women from a non WB ethnicity are also supportive of PIFU, 342 
although consideration should be made to ensure non-fluent English speakers are able to access 343 
the scheme. 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
 15 
REFERENCES 358 
 359 
 360 
Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I. 361 
(2005). Endometrial cancer. Lancet, 366(9484), 491-505. doi:10.1016/S0140-362 
6736(05)67063-8 363 
Beaver, K., Williamson, S., Sutton, C., Hollingworth, W., Gardner, A., Allton, B., . . . 364 
Martin-Hirsch, P. (2016). Comparing hospital and telephone follow-up for patients 365 
treated for stage-I endometrial cancer (ENDCAT trial): a randomised, multicentre, 366 
non-inferiority trial. BJOG. doi:10.1111/1471-0528.14000 367 
BMJ Editor's checklists 2016 [cited 2016 1 April]. Available from: 368 
http://www.bmj.com/about-bmj/resources-authors/article-types/research/editors-369 
checklists. 370 
Boyes, A. W., Girgis, A., D'Este, C., & Zucca, A. C. (2012). Prevalence and correlates of 371 
cancer survivors' supportive care needs 6 months after diagnosis: a population-based 372 
cross-sectional study. BMC Cancer, 12, 150. doi:10.1186/1471-2407-12-150 373 
Colombo, N., Preti, E., Landoni, F., Carinelli, S., Colombo, A., Marini, C., . . . Group, E. G. 374 
W. (2011). Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, 375 
treatment and follow-up. Ann Oncol, 22 Suppl 6, vi35-39. 376 
doi:10.1093/annonc/mdr374 377 
Drageset, S., Lindstrom, T. C., & Underlid, K. (2010). Coping with breast cancer: between 378 
diagnosis and surgery. J Adv Nurs, 66(1), 149-158. doi:10.1111/j.1365-379 
2648.2009.05210.x 380 
Drageset, S., Lindstrom, T. C., & Underlid, K. (2016). "I just have to move on": Women's 381 
coping experiences and reflections following their first year after primary breast 382 
cancer surgery. Eur J Oncol Nurs, 21, 205-211. doi:10.1016/j.ejon.2015.10.005 383 
Erzberger, C., & Prein, G. (1997). Triangulation: Validity and empirically-based hypothesis 384 
construction. Quality & Quantity, 31(2), 141-154.  385 
Fayers, P., & Bjordal, K. (2001). EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: 386 
EOTOC Publications. 387 
Gadducci, A., Cosio, S., Fanucchi, A., Cristofani, R., & Genazzani, A. R. (2000). An 388 
intensive follow-up does not change survival of patients with clinical stage I 389 
endometrial cancer. Anticancer Res, 20(3B), 1977-1984.  390 
Howard, A. F., Goddard, K., Tan de Bibiana, J., Pritchard, S., Olson, R., & Kazanjian, A. 391 
(2016). Adult childhood cancer survivors' narratives of managing their health: the 392 
unexpected and the unresolved. J Cancer Surviv, 10(4), 711-725. 393 
doi:10.1007/s11764-016-0517-8 394 
Leeson, S., Stuart, N., Sylvestre, Y., Hall, L., & Whitaker, R. (2013). Gynaecological cancer 395 
follow-up: national survey of current practice in the UK. BMJ Open, 3(7). 396 
doi:10.1136/bmjopen-2013-002859 397 
Lord, K., Ibrahim, K., Kumar, S., Mitchell, A. J., Rudd, N., & Symonds, R. P. (2013). Are 398 
depressive symptoms more common among British South Asian patients compared 399 
with British White patients with cancer? A cross-sectional survey. BMJ open, 3(6), 400 
e002650.  401 
Owen, P., & Duncan, I. D. (1996). Is there any value in the long term follow up of women 402 
treated for endometrial cancer? Br J Obstet Gynaecol, 103(7), 710-713.  403 
Parkin, D. M., Boyd, L., & Walker, L. C. (2011). 16. The fraction of cancer attributable to 404 
lifestyle and environmental factors in the UK in 2010. Br J Cancer, 105 Suppl 2, S77-405 
81. doi:10.1038/bjc.2011.489 406 
 16 
Plano Clark, V., & Creswell, J. (2010). Understanding research: a consumer's guide. Upper 407 
Saddle River, NJ: Prentice Hall - Merrill. 408 
Salani, R., Backes, F. J., Fung, M. F., Holschneider, C. H., Parker, L. P., Bristow, R. E., & 409 
Goff, B. A. (2011). Posttreatment surveillance and diagnosis of recurrence in women 410 
with gynecologic malignancies: Society of Gynecologic Oncologists 411 
recommendations. Am J Obstet Gynecol, 204(6), 466-478. 412 
doi:10.1016/j.ajog.2011.03.008 413 
Scott, N., & Aaronson, N. (2008). EORTC QLQ-C30 Reference Values. Brussels: EORTC 414 
Publications. 415 
Taneja, A., Su'a, B., & Hill, A. G. (2014). Efficacy of patient-initiated follow-up clinics in 416 
secondary care: a systematic review. Intern Med J, 44(12a), 1156-1160. 417 
doi:10.1111/imj.12533 418 
UK, C. R. Survival statistic for womb cancer | Cancer Research UK. Cancerresearchuk.org. 419 
2016 [cited 12 July 2016]. Available from: http://www.cancerresearchuk.org/about-420 
cancer/type/womb-cancer/treatment/statistics-and-outlook-for-womb-cancer#prog.  421 
UK, C. R. Uterine cancer incidence statistics 2016 [cited 2016 13 May]. Available from: 422 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-423 
cancer-type/uterine-cancer/incidence#heading-Two.  424 
Yoshiba, T., Takei, Y., Machida, S., Taneichi, A., Sato, N., Takahashi, S., . . . Fujiwara, H. 425 
(2016). Prognosis of endometrial cancer patients with and without symptoms at 426 
recurrence. J Obstet Gynaecol Res. doi:10.1111/jog.13112 427 
Zelman, D. C., Smith, M. Y., Hoffman, D., Edwards, L., Reed, P., Levine, E., . . . Dukes, E. 428 
(2004). Acceptable, manageable, and tolerable days: patient daily goals for 429 
medication management of persistent pain. J Pain Symptom Manage, 28(5), 474-487. 430 
doi:10.1016/j.jpainsymman.2004.02.022 431 
 432 
   433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 17 
Figure 1.  449 
 450 
EORTC Functioning Scale Scores (FSS).  451 
 452 
A) Physical functioning.  453 
6 months n=138, 12 months n= 104. Mann Whitney p=0.938. 454 
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 467 
B) Emotional functioning. 468 
6 months n=143, 12 months n=101. Mann Whitney p=0.813. 469 
 470 
 471 
 472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
C) Role functioning 483 
6 months n=147, 12 months n=104. Mann Whitney p=0.563 484 
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Figure 2. Symptoms scale score (SSS).  495 
 496 
 497 
A) Pain 498 
6 months n=145, 12 months n=105. Mann Whitney p=0.429 499 
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B) Fatigue 521 
6 months n=146, 12 months n=104. Mann Whitney p=0.250 522 
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Figure 3. EORTC Global Health Status Scores (GHSS).  Range from 0-100 with a high score 539 
indicating a high quality of life. 6 months n=146, 12 months n=106. Mann Whitney p=0.564. 540 
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